Canada Markets closed

Sosei Group Corporation (SOLTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
17.070.00 (0.00%)
At close: 01:44PM EST

Sosei Group Corporation

PMO Hanzomon
11th Floor 2-1 Kojimachi Chiyoda-ku
Tokyo 102-0083
Japan
81 3 5210 3290
https://soseiheptares.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees196

Key Executives

NameTitlePayExercisedYear Born
Mr. Shinichi TamuraFounder, Exec. Chairman, Representative Exec. Officer, Pres & CEO1.29MN/A1949
Mr. Chris CargillExec. Officer & CFO894.45kN/A1984
Dr. Malcolm Weir Ph.D.Exec. Officer & VP633.93kN/A1958
Mr. Hironoshin NomuraSr. VP of Investor Relations & Corp. StrategyN/AN/AN/A
Mr. Kazuhiko YoshizumiExec. Officer & Chief Compliance OfficerN/AN/A1954
Candelle ChongVP of Corp. Strategy & CommunicationsN/AN/AN/A
Dr. Tim TaskerExec. Officer & Chief Medical OfficerN/AN/A1964
Shinichiro NishishitaVP of Investor Relations & Head of Regulatory DisclosuresN/AN/AN/A
Mr. Tadayoshi YasuiExec. OfficerN/AN/A1959
Dr. Barry Kenny Ph.D.Chief Bus. Officer of Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sosei Group Corporation discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of AZD4635, an adenosine A2a antagonist, which is in Phase II clinical trial for the treatment of tumors and metastatic castration resistant prostate cancer; HTL0022562, a calcitonin gene related peptide antagonist, which is in pre-clinical stage to treat migraine and other severe headaches; PF-07081532 and PF-07054894, which are in Phase l for use in multiple therapeutic areas; HTL0014242, a mGlu5 small molecule negative-allosteric modulator, which is in Phase I clinical trial to treat neurological order; GPR35 agonist to treat inflammatory bowel disease; and KY1051, which is in preclinical stage for the treatment of immuno-oncology. It also offers HTL0016878, a muscarinic M4 receptor agonist, which is in Phase I clinical trial for the treatment of Alzheimer's disease; SSTR agonist, a novel somatostatin peptide agonist, which is in Phase I clinical trial to treat endocrine disorders; GLP-1 antagonist, which is in pre-clinical stage for the treatment of severe hypoglycaemia in rare diseases; H4 antagonist, which is in preclinical stage to treat atopic dermatitis; EP4 antagonist, which is in preclinical stage to mediate PGE2 immunosuppression; GLP-2 agonist, a potent glucagon-like peptide-2 agonist, which is in pre-clinical stage to treat intestinal disorder; GPR52 agonist to treat of neurology disease; and PAR2 mAb for the treatment of atopic dermatitis. Sosei Group Corporation has a strategic collaboration with Kymab; PeptiDream Inc; Pfizer; AbbVie; Biohaven; GSK; AstraZeneca; Novartis; Genentech; Takeda Pharmaceutical Company Limited; and Metrion Biosciences Limited. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.

Corporate Governance

Sosei Group Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.